Log In
Print
BCIQ
Print
Print this Print this
 

GDC-0919, NLG919, RG6078

  Manage Alerts
Collapse Summary General Information
Company NewLink Genetics Corp.
DescriptionOral small molecule indoleamine 2,3-dioxygenase (INDO; IDO) pathway inhibitor
Molecular Target Indoleamine 2,3-dioxygenase (INDO) (IDO)
Mechanism of ActionIndoleamine 2,3-dioxygenase (INDO) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat recurrent advanced solid tumors
Regulatory Designation

Partner

Roche


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$150.0M

$1,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today